- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07947849
Efficacy of Postbiotic Supplementation in Improving Antioxidant Status
Effects of Postbiotic Supplementation in Improving Total Antioxidant Status in Healthy Adults
This study will evaluate changes in salivary antioxidant capacity, oxidative stress biomarkers, and self-perceived general well-being during eight weeks of postbiotic supplementation in generally healthy adults.
Thirty-six participants aged 18 years or older will receive MettaBion Liquid twice daily for eight weeks. Assessments will be conducted before supplementation and at Weeks 4 and 8. Saliva samples will be analysed for total antioxidant capacity, malondialdehyde, 3-nitrotyrosine, and 8-hydroxy-2'-deoxyguanosine. General well-being will be assessed using a visual analogue scale.
This prospective, single-arm study will estimate within-participant changes and their variability to inform the design and sample-size planning of a future randomised, placebo-controlled trial.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This prospective, single-arm, open-label study will evaluate changes in salivary antioxidant capacity, oxidative stress biomarkers, and self-perceived general well-being following eight weeks of postbiotic supplementation in generally healthy adults. The study will recruit 36 participants aged 18 years or older. Assessments will be conducted at baseline, Week 4, and Week 8.
Participants will consume MettaBion Liquid orally for eight weeks, taking one sachet after breakfast and one sachet after dinner each day. Each sachet contains 5,000 mg of proprietary cell-free metabolite preparations derived from Lactobacillus plantarum, providing a total daily intake of 10,000 mg of the preparation. Adherence will be monitored using a participant compliance form.
Unstimulated saliva samples will be collected at each assessment visit to measure total antioxidant capacity (T-AOC), malondialdehyde (MDA), 3-nitrotyrosine (3-NT), and 8-hydroxy-2'-deoxyguanosine (8-OHdG) using Elabscience assay kits. These measurements will assess antioxidant capacity and markers of lipid peroxidation, protein nitration, and oxidative DNA damage, respectively. Participants will also assess their general well-being using a visual analogue scale ranging from 1 to 10, with higher scores indicating better perceived well-being.
The primary outcome will be the change in salivary T-AOC from baseline to Week 8. Secondary outcomes will include the change in salivary T-AOC from baseline to Week 4 and changes in salivary MDA, 3-NT, 8-OHdG, and general well-being scores from baseline to Weeks 4 and 8.
Eligible participants must be generally healthy, willing to follow the study procedures and attend follow-up visits, and able to provide written informed consent before enrolment. Individuals will be excluded if they are currently taking supplements intended to improve antioxidant status, antibiotics, antiviral medicines, or prebiotic or postbiotic supplements; have undergone major surgery within the preceding six months; or are pregnant or breastfeeding.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Chung Keat Tan, PhD
- Phone Number: +6017-5063305
- Email: cktan.jsci@gmail.com
Study Locations
-
-
Kuala Lumpur
-
Cheras, Kuala Lumpur, Malaysia, 56000
- UCSI University
-
Contact:
- Eugenie Sin Sing Tan, PhD
- Phone Number: +6016-8924008
- Email: eugenietan@ucsiuniversity.edu.my
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Generally healthy adults aged 18 years or older.
- Willing to follow the study plan and attend follow-up visits.
- Willing to provide written informed consent before enrolment.
Exclusion Criteria:
- Currently taking supplements intended to improve antioxidant status.
- Currently taking antibiotics or antiviral medicines.
- Currently taking prebiotic or postbiotic supplements.
- Major surgery within the previous six months.
- Pregnant or breastfeeding.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: MettaBion Liquid Supplementation
Participants will consume one sachet of MettaBion Liquid after breakfast and one sachet after dinner daily for eight weeks. Each sachet contains 5,000 mg of proprietary cell-free metabolite preparations derived from Lactobacillus plantarum. |
5,000 mg of proprietary cell-free metabolite preparations derived from Lactobacillus plantarum. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in salivary total antioxidant capacity from baseline to Week 8
Time Frame: Baseline and Week 8
|
Change in salivary total antioxidant capacity measured using an Elabscience assay kit. |
Baseline and Week 8
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in salivary malondialdehyde
Time Frame: Baseline and Week 8
|
Change in salivary malondialdehyde, a marker of lipid peroxidation, measured using an Elabscience assay kit. |
Baseline and Week 8
|
|
Change in salivary 3-nitrotyrosine
Time Frame: Baseline and Week 8
|
Change in salivary 3-nitrotyrosine, a marker of protein nitration, measured using an Elabscience assay kit. |
Baseline and Week 8
|
|
Salivary 8-hydroxy-2'-deoxyguanosine (8-OHdG)
Time Frame: Baseline and Week 8
|
Change in salivary 8-hydroxy-2'-deoxyguanosine, a marker of oxidative DNA damage, measured using an Elabscience assay kit. |
Baseline and Week 8
|
|
Self-perceived general well-being
Time Frame: Baseline, Week 4, and Week 8
|
Change in self-perceived general well-being assessed using a visual analogue scale ranging from 1 to 10, with higher scores indicating better general well-being. |
Baseline, Week 4, and Week 8
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- METTABION - ANTIOXIDANT
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
De-identified individual participant data underlying the published results will be made available to qualified researchers upon reasonable request to the principal investigator. Access will be subject to review of the proposed research purpose, consistency with participant consent and institutional ethics requirements, and a signed data use agreement.
IPD Sharing Time Frame
Beginning six months after publication of the study results and continuing for five years.
IPD Sharing Access Criteria
Researchers must submit a methodologically sound proposal outlining the intended use of the data to the principal investigator.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.